P-Glycoprotein Is a Major Determinant of Norbuprenorphine Brain Exposure and Antinociception

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2012-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.112.193433PMID 22739506PMCID PMC3464040
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice

  2011cited by this paper
• Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients.

  2011cited by this paper
• Chemical and enzyme-assisted syntheses of norbuprenorphine-3-β-D-glucuronide.

  2011cited by this paper
• Blood-Brain Barrier Differentiation

  2011cited by this paper
• Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.

  2011cited by this paper
• Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

  2010cited by this paper
• Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

  2010cited by this paper
• Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines.

  2010cited by this paper
• Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.

  2009cited by this paper
• The Metabotropic Glutamate Receptor Subtype 5 Antagonist Fenobam Is Analgesic and Has Improved in Vivo Selectivity Compared with the Prototypical Antagonist 2-Methyl-6-(phenylethynyl)-pyridine

  2009cited by this paper
• The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism.

  2009cited by this paper
• Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.

  2009influential reference
• Pharmacokinetics and Pharmacodynamics of Alfentanil in P-Glycoprotein-Competent and P-Glycoprotein-Deficient Mice: P-Glycoprotein Efflux Alters Alfentanil Brain Disposition and Antinociception

  2007cited by this paper
• Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

  2007cited by this paper
• Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein.

  2007cited by this paper
• Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats

  2007cited by this paper
• Role of human placental efflux transporter P-glycoprotein in the transfer of buprenorphine, levo-alpha-acetylmethadol, and paclitaxel.

  2006cited by this paper
• In Vivo Activation of Human Pregnane X Receptor Tightens the Blood-Brain Barrier to Methadone through P-Glycoprotein Up-Regulation

  2006cited by this paper
• P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice.

  2006cited by this paper
• Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.

  2006cited by this paper
• Isolation and culture of microvascular endothelial cells from murine spinal cord.

  2006cited by this paper
• Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.

  2006cited by this paper
• Role of Human Placental Efflux Transporter P-Glycoprotein in the Transfer of Buprenorphine, Levo-α-Acetylmethadol, and Paclitaxel

  2006cited by this paper
• Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography

  2005cited by this paper
• Physiology of the blood–brain barrier and its consequences for drug transport to the brain

  2005cited by this paper
• THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

  2005cited by this paper
• Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties

  2004cited by this paper
• Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood–brain barrier of Abcb1a gene knockout mice

  2004cited by this paper
• Variable modulation of opioid brain uptake by P-glycoprotein in mice.

  2004cited by this paper
• The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

  2004cited by this paper
• Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers.

  2003cited by this paper
• Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption.

  2003cited by this paper
• Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein

  2002cited by this paper
• A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolite, norbuprenorphine, and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies.

  2002cited by this paper
• In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.

  2002cited by this paper
• Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.

  2001cited by this paper
• Rational use of in vitro P-glycoprotein assays in drug discovery.

  2001cited by this paper
• Opiate-induced Analgesia Is Increased and Prolonged in Mice Lacking P-glycoprotein

  2000cited by this paper
• Morphine Antinociception Is Enhanced in mdr1a Gene-Deficient Mice

  2000influential reference
• The role of P‐glycoprotein in blood‐brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (−/−) and mdr1a (+/+) mice

  1999cited by this paper
• Drug transfer across the blood‐brain barrier and improvement of brain delivery

  1999cited by this paper
• Role of P-Glycoprotein on the CNS Disposition of Amprenavir (141W94), an HIV Protease Inhibitor

  1999cited by this paper
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

  1998cited by this paper
• Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers.

  1997cited by this paper
• Drug Delivery to the Brain

  1997cited by this paper
• Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine.

  1997cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• Possible involvement of mu 2-opioid receptor-mediated mechanisms in morphine-induced enhancement of the pentobarbital-induced loss of the righting reflex in the mouse.

  1996cited by this paper
• Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.

  1995cited by this paper
• Clinical pharmacology of buprenorphine: Ceiling effects at high doses

  1994cited by this paper
• Morphine-induced straub tail response: mediated by central mu2-opioid receptor.

  1994cited by this paper
• Effects of the subcutaneous administration of enkephalins on tail-flick response and righting reflex of developing rats.

  1992cited by this paper
• AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT

  1977cited by this paper
• Effects of opiates and opiate antagonists on the Straub tail reaction in mice

  1969cited by this paper
• The anatomical basis of the straub phenomenon.

  1960cited by this paper

• Methadone and Buprenorphine as Medication for Addiction Treatment Diversely Affect Inflammation and Craving Depending on Their Doses

  2025cites this paper
• Pharmacogenomics of buprenorphine - a narrative review

  2025influential citation
• Disposition Factors Impacting Buprenorphine Salivary Gland Accumulation and Oral Fluid Exposure

  2025cites this paper
• Reconsidering the usefulness of long-term high-dose buprenorphine

  2024influential citation
• Opioid metabolism and drug-drug interaction in cancer

  2024cites this paper
• Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder

  2024cites this paper
• Clinical Therapy Dose Optimization of Sublingual Buprenorphine in Poorly Adherent Pregnant Patients: A PBPK Translational Modelling Study

  2024cites this paper
• EPD1504: a novel μ-opioid receptor partial agonist attenuates obsessive–compulsive disorder (OCD)-like behaviors

  2023cites this paper
• Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats

  2023cites this paper
• Detection, chemical analysis, and pharmacological characterization of dipyanone and other new synthetic opioids related to prescription drugs

  2023cites this paper
• Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone

  2023cites this paper
• An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine

  2023cites this paper
• Maternal and Fetal Expression of ATP-Binding Cassette and Solute Carrier Transporters Involved in the Brain Disposition of Drugs.

  2023cites this paper
• Identification of Potential Insect Growth Inhibitor against Aedes aegypti: A Bioinformatics Approach

  2022cites this paper
• The Impact of P-Glycoprotein on Opioid Analgesics: What’s the Real Meaning in Pain Management and Palliative Care?

  2022cites this paper
• Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.

  2022cites this paper
• Central Nervous System Distribution of Buprenorphine in Pregnant Sheep, Fetuses and Newborn Lambs After Continuous Transdermal and Single Subcutaneous Extended-Release Dosing.

  2022cites this paper
• The history and pharmacology of buprenorphine: New advances in cats.

  2022cites this paper
• Buprenorphine-Related Deaths in North Carolina from 2010-2018.

  2021cites this paper
• Mechanisms of respiratory depression induced by the combination of buprenorphine and diazepam in rats.

  2021cites this paper
• Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists.

  2021cites this paper
• An overview on the two recent decades’ study of peptides synthesis and biological activities in Iran

  2021cites this paper
• Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site

  2021cites this paper
• Classics In Chemical Neuroscience: Buprenorphine.

  2020cites this paper
• Re-evaluating how low intrinsic efficacy and apparent bias for G protein activation relates to the improved side effect profiles of new opioid agonists

  2020cites this paper
• An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Receptor Modulator Buprenorphine

  2020cites this paper
• Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study

  2020cites this paper
• What the lab can and cannot do: clinical interpretation of drug testing results

  2020cites this paper
• Determination of the temperature causing a nociceptive response in the tail of albino BALB/c mice.

  2020cites this paper
• Pharmacotherapy of neonatal opioid withdrawal syndrome: a review of pharmacokinetics and pharmacodynamics

  2020cites this paper
• Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates

  2020cites this paper
• A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain

  2020cites this paper
• Efficient Synthesis of Norbuprenorphines Coupled with Enkephalins and Investigation of Their Permeability

  2019cites this paper
• Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations

  2019cites this paper
• Hierarchical Virtual Screening of Potential Insectides Inhibitors of Acetylcholinesterase and Juvenile Hormone from Temephos

  2019cites this paper
• In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome

  2019cites this paper
• Pain Therapy Guided by Purpose and Perspective in Light of the Opioid Epidemic

  2018cites this paper
• The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome

  2018cites this paper
• Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity

  2018cites this paper
• Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option

  2018cites this paper
• Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit

  2018cites this paper
• What Parenteral Opioids to Use in Face of Shortages of Morphine, Hydromorphone, and Fentanyl

  2018cites this paper
• Determination of the temperature causing a nociceptive response in the tail of albino BALB/c mice.

  2018cites this paper
• Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation

  2018cites this paper
• Stammesspezifische Unterschiede in der analgetischen Wirkung von Buprenorphin bei der Maus

  2018cites this paper
• Understanding Pregnancy-induced Changes in the Disposition of Norbuprenorphine, Metformin and Glyburide in Mice and Humans for Optimizing Drug Therapy during Pregnancy

  2018cites this paper
• A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration

  2017cites this paper
• Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study

  2017cites this paper
• P‐gp/ABCB1 exerts differential impacts on brain and fetal exposure to norbuprenorphine

  2017cites this paper
• Comparative Anesthesia and Analgesia of Dogs and Cats

  2017cites this paper
• Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center

  2017cites this paper
• Intranasal mucoadhesivemicroemulsion for neuroprotective effect of curcuminin mptp induced Parkinson model

  2017cites this paper
• Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interaction

  2016cites this paper
• 20 th North American ISSX Meeting A 1 – Validation of the Geneva cocktail for cytochrome P 450 phenotyping using innovative dried blood sampling method

  2016cites this paper
• Comparing the Quantitation of Opiates from Possible Drug Overdose Cases Using Results of Blood Analysis and Liver Analysis

  2016cites this paper
• Clinical Use of Buprenorphine for Anesthesia and Pain Management in Japan

  2016cites this paper
• Plasma concentrations of buprenorphine following a single subcutaneous administration of a sustained release formulation of buprenorphine in sheep.

  2016cites this paper
• Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging

  2016cites this paper
• Rifampicin decreases exposure to sublingual buprenorphine in healthy subjects

  2016cites this paper
• Sedation and Analgesia in Transportation of Acutely and Critically Ill Patients.

  2016cites this paper
• 20th North American ISSX Meeting

  2016cites this paper
• Role of drug transporters: an overview based on knockout animal model studies

  2015cites this paper
• An Unusual Case of Death Probably Triggered by the Association of Buprenorphine at Therapeutic Dose with Ethanol and Benzodiazepines and with Very Low Norbuprenorphine Level

  2015cites this paper
• Determination of buprenorphine, norbuprenorphine and naloxone in fingernail clippings and urine of patients under opioid substitution therapy.

  2015cites this paper
• Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions

  2015cites this paper
• Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.

  2015cites this paper
• Endogenous opiates and behavior: 2012.

  2013cites this paper
• Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine

  2013influential citation
• A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice

  2013cites this paper
• Gender and strain contributions to the variability of buprenorphine-related respiratory toxicity in mice.

  2013cites this paper
• Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry.

  2013cites this paper